Selegiline is a monoamine oxidase-B (MAO-B) inhibitor used in the treatment of Parkinson's disease and major depressive disorder. It acts by irreversibly inhibiting the enzyme MAO-B, which metabolizes dopamine in the brain, thereby increasing dopamine availability and extending the duration of levodopa's effect. [1]
| Property | Value | [2]
|----------|-------| [3]
| Drug Class | MAO-B Inhibitor | [4]
| Approval Status | FDA Approved (1989) | [5]
| Brand Names | Eldepryl, Zelapar, Emsam (transdermal) | [6]
| Mechanism | Irreversible MAO-B inhibition | [7]
| Route of Administration | Oral, Transdermal | [8]
| Half-life | 1-2 hours (oral), 18-25 hours (transdermal) |
Selegiline selectively and irreversibly inhibits monoamine oxidase type B (MAO-B) in the brain:
| Parameter | Value |
|---|---|
| Bioavailability | ~25% (oral) |
| Protein Binding | ~90% |
| Metabolism | Hepatic (CYP450 enzymes) |
| Elimination | Renal (~80%) |
| Duration of MAO-B Inhibition | Irreversible (requires new enzyme synthesis, ~2 weeks) |
| Interacting Drug | Effect |
|---|---|
| SSRIs (fluoxetine, sertraline) | Serotonin syndrome risk |
| Tyramine-rich foods | Hypertensive crisis (high doses) |
| Meperidine | Potentially fatal interaction |
| TCAs | Serotonin syndrome risk |
The study of Selegiline Mao B Inhibitor For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Parkinson Study Group. "Effect of selegiline on the progression of Parkinson's disease." JAMA. 1989;261(19):2883-2898. JAMA. 1989. ↩︎
The Selegiline Research Group. "A controlled trial of selegiline in Parkinson disease." Arch Neurol. 1993;50(10):1023-1029. Arch Neurol. 1993. ↩︎
Youdim MB, Bakhle YS. "Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness." Br J Pharmacol. Br J Pharmacol. 2006. ↩︎
Riederer P, Laux G. "MAO-inhibitors in Parkinson's disease." Exp Neurobiol. Exp Neurobiol. 2011. ↩︎
Factor SA, Weiner WJ. "Selegiline in the treatment of Parkinson's disease." Expert Opin Pharmacother. Expert Opin Pharmacother. 2002. ↩︎
Birkmayer W, Riederer P, Youdim MB. "Selegiline (Eldepryl): from tissue culture to neuronal rescue." J Neural Transm Suppl. J Neural Transm Suppl. 1996. ↩︎
Knoll J. "The pharmacology of selegiline ((-)-deprenyl)." J Neural Transm Suppl. J Neural Transm Suppl. 1994. ↩︎
Amiri S, et al. "Selegiline in the treatment of major depressive disorder." Neuropsychiatr Dis Treat. Neuropsychiatr Dis Treat. 2014. ↩︎